Control Bionics Ltd. (AU:CBL)
ASX:CBL
Want to see AU:CBL full AI Analyst Report?
CBL Stock Chart & Stats
AU$0.06
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.06
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.09
Previous CloseN/A
Volume65.91K
Average Volume (3M)173.99K
Market Cap
AU$28.01M
Enterprise ValueAU$18.92M
Total Cash (Recent Filing)AU$3.06M
Total Debt (Recent Filing)AU$258.10K
Price to Earnings (P/E)―
Beta0.16
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding411,961,880
10 Day Avg. Volume327,267
30 Day Avg. Volume173,987
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.44
Price to Sales (P/S)1.29
P/FCF Ratio-1.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained top-line growth (~16% year) signals durable market adoption of the company’s assistive-technology offerings. Over 2-6 months this supports scaling opportunities, potential operating leverage as volumes rise, and stronger commercial traction in niche medical-device segments.
Conservative LeverageA low debt load provides financial flexibility to fund R&D or absorb operating shortfalls without heavy interest burdens. Over the medium term this reduces bankruptcy risk and creates optionality for strategic investments or partnerships without immediate refinancing pressure.
Niche Assistive-Tech Market PositionA focused product set for severe speech and mobility impairments gives structural demand from healthcare providers and patient groups. This specialization creates durable competitive advantages: high switching costs, clinical validation needs, and recurring replacement/upgrade opportunities.
Bears Say
Persistent UnprofitabilityOngoing negative EBIT and net margins indicate the company is not yet converting revenue into sustainable profits. Over months this will press margins, constrain reinvestment capacity, and necessitate external funding or structural cost changes to reach durable profitability.
Negative Operating Cash FlowNegative operating cash flow and declining free cash flow growth signal weaknesses in cash generation and conversion. This structural cash shortfall can force dilutive equity raises or debt, limiting strategic choices and increasing financial risk over the medium term.
Negative Return On EquityA negative ROE shows shareholder capital is not producing returns, reflecting operational inefficiency or high upfront costs. Persisting this way undermines investor confidence, may raise governance scrutiny, and makes raising capital more expensive or dilutive long term.
Control Bionics Ltd. News
CBL FAQ
What was Control Bionics Ltd.’s price range in the past 12 months?
Control Bionics Ltd. lowest share price was AU$0.03 and its highest was AU$0.09 in the past 12 months.
What is Control Bionics Ltd.’s market cap?
Control Bionics Ltd.’s market cap is AU$28.01M.
When is Control Bionics Ltd.’s upcoming earnings report date?
Control Bionics Ltd.’s upcoming earnings report date is Aug 26, 2026 which is in 107 days.
How were Control Bionics Ltd.’s earnings last quarter?
Control Bionics Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.011.
Is Control Bionics Ltd. overvalued?
According to Wall Street analysts Control Bionics Ltd.’s price is currently Overvalued.
Does Control Bionics Ltd. pay dividends?
Control Bionics Ltd. does not currently pay dividends.
What is Control Bionics Ltd.’s EPS estimate?
Control Bionics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Control Bionics Ltd. have?
Control Bionics Ltd. has 411,961,880 shares outstanding.
What happened to Control Bionics Ltd.’s price movement after its last earnings report?
Control Bionics Ltd. reported an EPS of -AU$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.667%.
Which hedge fund is a major shareholder of Control Bionics Ltd.?
Currently, no hedge funds are holding shares in AU:CBL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Control Bionics Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.29%
12-Months-Change
Fundamentals
Return on Equity
-98.14%
Trailing 12-Months
Asset Growth
12.36%
Trailing 12-Months
Company Description
Control Bionics Ltd.
Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia and North America. The company offers NeuroNode Trilogy and NeuroNode3 systems that allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. It also provides Cosmos Connect, a device to control a range of devices, including wheelchairs, dining robots, and gaming systems; Uno Touch, a speech generating device; and other sensors for multiple applications. The company was formerly known as Control Bionics Holdings Pty Limited and changed its name to Control Bionics Limited in September 2020. Control Bionics Limited was incorporated in 2005 and is based in Camberwell, Australia.
Technical Analysis
Options Prices
Currently, No data available
---